Could a Triple-Drug cocktail tame tough breast cancer?
NCT ID NCT04732598
First seen Apr 28, 2026 · Last updated Apr 28, 2026
Summary
This study tested whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy (paclitaxel) and a targeted drug (bevacizumab) helps people with a common type of advanced breast cancer (HR-positive, HER2-negative). The trial enrolled 281 participants whose cancer had spread or could not be removed by surgery. The goal was to see if the three-drug combination slowed cancer growth better than the two-drug combination alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Institute Hospital of JFCR
Tokyo, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.